ARTICLE | Regulation
Pandemic could give advantage to newly approved MS latecomer ofatumumab
Novartis’ once-monthly anti-CD20 mAb is only auto-injectable MS drug targeting B cells
August 20, 2020 11:40 PM UTC
With FDA’s approval of Kesimpta ofatumumab for multiple sclerosis, Novartis could become the latest company to reap the added benefits of launching a drug with a convenient route of administration during the pandemic.
FDA approved the once-monthly, auto-injectable anti-CD20 mAb to treat relapsing forms of MS on Thursday after a three-month delay in the agency’s review. An IV version of the drug has been marketed as Arzerra for chronic lymphocytic leukemia (CLL) for more than a decade ago...
BCIQ Target Profiles